Navigation Links
Fate Therapeutics Announces the Appointment of William H. Rastetter as Chairman of its Board of Directors and Interim CEO
Date:12/14/2011

SAN DIEGO, Dec. 14, 2011 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that it has appointed William H. Rastetter Ph.D. as Chairman and Interim Chief Executive Officer.  Dr. Rastetter served as Chief Executive Officer of IDEC Pharmaceuticals from December 1986 through November 2003, and as Chairman from May 1996 to November 2003.  Upon the merger of IDEC Pharmaceuticals and Biogen in November 2003, Dr. Rastetter served as Executive Chairman of Biogen Idec until the end of 2005.

"Fate's lead therapeutic, ProHema, has already demonstrated potential benefit to patients that are stricken with life-threatening hematologic malignancies and are in need of hematopoietic reconstitution.  I am excited to shepherd ProHema's further clinical development and its access to patients," said Dr. Rastetter.  "I am also impressed with Fate's approach to identifying therapeutic intervention points in adult stem cell biology, which has translated into a promising pipeline of product candidates.  I look forward to collaborating with the Fate team and board of directors to continue to drive forward in the development of innovative regenerative medicines."

Fate Therapeutics announced yesterday promising clinical results from a Phase 1b trial of ProHema as part of double-umbilical cord blood (UCB) transplants in adult patients with hematologic malignancies who have undergone reduced-intensity conditioning therapy.  The data were presented at the 53rd annual American Society of Hematology (ASH) meeting.  Of the twelve subjects that received ProHema, the median time to neutrophil recovery (> 500 cells/uL) was 17.5 days, which compares favorably to historical norms for patients undergoing double-UCB.  In addition, ProHema provided the dominant source of hematopoiesis in ten of the twelve subjects, suggesting that treatment with ProHema may confer preferential engraftment.

"Given Dr. Rastetter's industry experience in developing and commercializing highly innovative products, such as Rituxan®, we feel privileged that he will join our efforts in creating a world-leading therapeutics enterprise from our foundational science in adult stem cell biology," said John Mendlein, Ph.D., founder and Vice Chairman of Fate Therapeutics.  "Dr. Rastetter joins us at a transformational time as our innovative ProHema product advances closer to patient and commercialization reality.  His proven leadership in translating new therapeutic modalities into successful products enhances our team and our vision to deliver life-changing therapeutics to patients."

Dr. Rastetter also serves as the Chairman of Illumina, Inc., of Neurocrine Biosciences, Inc., and of Receptos, Inc., and is a partner in the venture capital firm Venrock.  Dr. Mendlein, in addition to his role as founder and Vice Chairman of Fate Therapeutics, is currently the Executive Chairman and CEO of aTyr Pharma.

About ProHema

ProHema is a first-in-class therapeutic consisting of pharmacologically-enhanced hematopoietic stem cells (HSC), where pharmacologic modulation imparts a greater than 20-fold up-regulation of key biological factors for enhanced HSC homing and proliferation.  Fate Therapeutics has completed a Phase 1b clinical study for ProHema in hematologic malignancy patients undergoing double-umbilical cord HSC transplant, and is exploring the therapeutic benefits of ProHema in other settings of HSC transplantation. The Company has submitted to the FDA a clinical protocol to evaluate ProHema in a single-cord blood allogeneic transplant setting, and intends to begin enrolling patients into that study within the next three months.

About Fate Therapeutics, Inc.

Fate Therapeutics is an innovative biotechnology company developing novel stem cell modulators (SCMs), biologic or small molecule compounds that guide cell fate, to treat patients with very few therapeutic options.  Fate Therapeutics' lead clinical candidate, ProHema, consists of pharmacologically-enhanced hematopoietic stem cells (HSCs) designed to improve HSC support during the normal course of a stem cell transplant for the treatment of patients with hematologic malignancies.  The Company is also advancing a robust pipeline of human recombinant proteins, each with novel mechanisms of action, for skeletal muscle, beta-islet cell, and post-ischemic tissue regeneration.   Fate Therapeutics also applies its award-winning, proprietary, induced pluripotent stem cell (iPSC) technology to offer a highly efficient platform to recapitulate human physiology for commercial scale drug discovery and therapeutic use.  Fate Therapeutics is headquartered in San Diego, CA, with a subsidiary in Ottawa, Canada.  For more information, please visit www.fatetherapeutics.com.


'/>"/>
SOURCE Fate Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA™ Oral Calcitonin
2. Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference
3. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
4. MarketsandMarkets: Chronic Lymphocytic Leukemia Therapeutics Market Worth $2.2 Billion by 2020
5. Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
6. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
7. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
8. Aratana Therapeutics Completes $15 Million Series B Financing
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
11. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... , Aug. 16, 2017  Kingfisher Talent, the ... development, and Virdis Group, global executive search specialists in the ... enables clients to leverage the expertise and reach of both ... here in the Boston biotech hub, ... leadership talent throughout the US, Canada ...
(Date:8/15/2017)... , ... August 15, 2017 , ... ... biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch of the new ... steps needed to gain kinetic binding data for a wide range of molecules, ...
(Date:8/15/2017)... , ... August 15, 2017 , ... ... family of 6” modular downlights designed to stay tightly sealed and perform efficiently ... where damp and wet location listings just aren't enough, such as: hospitals; behavioral ...
(Date:8/15/2017)... ... 15, 2017 , ... JULABO USA introduces its new website ... makes it easy to navigate through the site whether you’re in the office, ... information, educational industry content and visit the company’s social media accounts, all on ...
Breaking Biology Technology:
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
(Date:3/23/2017)... 23, 2017 The report "Gesture Recognition and Touchless Sensing ... Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is expected ... 29.63% between 2017 and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... March 21, 2017 Optimove , ... by retailers such as 1-800-Flowers and AdoreMe, today ... Recommendations and Replenishment. Using Optimove,s machine learning algorithms, ... product and replenishment recommendations to their customers based ... predictions of customer intent drawn from a complex ...
Breaking Biology News(10 mins):